To view Article Recommendations, you must have an active subscription.
If your access has expired, you can subscribe at $9.95 per month, the first month of your subscription will be free of charge.
If you think you should be able to access this content, please contact us.
New to F1000? See this week’s top article below for a free preview of a Recommendation.
Laboratoire de Neurophysiologie et Neuropsychologie, Université de la Méditerranée, Marseille, France
Department of Neurology and Pharmacology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
Hôpital Neurologique, Hospices Civils de Lyon, Lyon, France
- » Anti-epileptic drugs
- » Basic mechanisms of seizures
- » Behavioral/psychosocial problems in epilepsy
- » Brain stimulation in epilepsy
- » Childhood epilepsy syndromes
- » Electroencephalography
- » Epileptogenesis and anti-epileptogenesis
- » Genetics of epilepsy
- » Imaging in epilepsy
- » Non-epileptic seizures
- » Partial epilepsies
- » Primary generalized epilepsies
- » Special issues for women with epilepsy
- » Status epilepticus
- » Surgical therapy
This paper addresses the clinically important issue of treating persons with severe epilepsy and co-morbid attention-deficit-hyperactivity disorder (ADHD). It demonstrates that low doses of methylphenidate can be issued safely and effectively to treat ADHD in...
TOP RATED ARTICLE THIS WEEK [FREE TO VIEW]
1 Recommendation, most recent by
Get instant access to Article Recommendations from more than 5,000 expert scientists and clinical researchers, assisted by 5,000 associates, by taking out a monthly subscription. The first month of your subscription will be free of charge.
Start your personal subscription today.Subscribe for $9.95/month
Send a recommendation to your institution's librarian or information manager to request an extended free trial for all users.Recommend to your Librarian
If you are a librarian or information manager, you may request an extended free trial for your academic or corporate institution.Request an Institutional Trial
your institution might be eligible for free access via our sponsorship scheme. Check our sponsorship page.